News

Infant ibuprofen voluntary recall expanded to 3 more products

By Bob D'Angelo, Cox Media Group National Content Desk
Jan 31, 2019

Three more lots of infant liquid ibuprofen have been included in a voluntary recall because of concerns that there are higher levels of concentration for the medicine, Newsweek reported Thursday.

>> Read more trending news

In a news release, Tris Pharma, Inc., of Monmouth Junction, New Jersey, said Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, is a pain reliever and fever reducer and sold in half-ounce and 1-ounce bottles at CVS Pharmacy and Walmart stores across the United States.

The three lots, labeled 4718, 00717005A and 00717006A, were added to the three products (00717009A; 00717015A; 00717024A) whose recall was announced in December 2018.

Some units from those six lots contain Ibuprofen concentrationas high as 10 percent above the specified limit, Tris Pharma said in its news release.

According to a news release by the Food and Drug Administration, "Studies have shown that safety issues or toxicity is generally accepted to be a concern in infants at doses in excess of 700 percent of the recommended dose.1 To date, no serious adverse events have been reported related to this recall."

The recall by Tris Pharma includes the following products:

Here are the previous recalls::

Customers with questions can call Tris Pharma’s customer service line at 732-940-0358 from 8 a.m. EST to 5 p.m. PST Monday through Friday or send an email to micc_tris@vigilarebp.com.

About the Author

Bob D'Angelo, Cox Media Group National Content Desk

More Stories